Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...

1. Brenner A, Youssef M, Kumthekar P, et al. Rhenium (¹⁸⁶Re) obisbemeda (rhenium nanoliposome, ¹⁸⁶RNL) for the treatment of ...

Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

CEO Carl Hansen highlighted the company's progress in its transition to a clinical-stage biotech with the advancement of its two lead programs, ABCL635 and ABCL575. ABCL635, a potential first-in-class ...

Study at the University of Colorado Anschutz Cancer Center builds on preclinical data showing that cirtuvivint plus PARP inhibition overcame resistance in preclinical models of high‑grade serous ovari ...

Aura Biosciences, Inc. recently presented positive Phase 1 trial results for its investigational treatment, bel-sar, targeting non-muscle invasive bladder cancer (NMIBC) at the 40th Annual European ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prior to this trial, CS014 had positive outcomes in an ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...

Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...

High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...

Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated ...